Therapy Areas: Hereditary Disorders
US FDA grants fast track designation to Proteostasis Therapeutics for cystic fibrosis program
6 April 2018 -

The United States Food and Drug Administration (FDA) has granted fast track designation to United States-based Proteostasis Therapeutics for its triple combination program to treat cystic fibrosis, it was reported yesterday.

The firm's proprietary triple combination includes a novel cystic fibrosis transmembrane conductance regulator amplifier, third generation corrector and potentiator, called PTI-428, PTI-801 and PTI-808, respectively.

The company had previously announced that the protocol for its triple combination clinical study, which it plans to initiate in the current quarter, has received endorsement and a high strategic fit score from the Therapeutics Development Network and the Clinical Trial Network, the drug development arms of the Cystic Fibrosis Foundation and the European CF Society, respectively.

The FDA's fast track designation is designed to facilitate the development and accelerate the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical requirements.

Login
Username:

Password:


Related Headlines

Synedgen Names Parker as Chief Business Officer

Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis, According to Gilead and Galapagos

Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis

Vertex, Genomics Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines

Vertex Receives a Positive PBAC Recommendation for Reimbursement of Orkambi to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation

ELITechGroup Biomedical Systems Launches Macroduct Advanced–A Sweat Induction and Collection Method Cleared by the FDA

FDA Approves Kalydeco as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford Biomedica Partner on Gene Therapy for Cystic Fibrosis

Motif Bio gets Notice of Allowance for two US patents

Oxford BioMedica collaborates with UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford Biomedica Partner on Gene Therapy for Cystic Fibrosis

Oxford BioMedica forms cystic fibrosis partnership

Celtaxsys announces clinically meaningful improvements in phase two cystic fibrosis trial of Acebilustat

Data from the ASSURE Study of Long-Term Use of Relizorb Published in Journal of Pediatric Gastroenterology and Nutrition, Alcresta Therapeutics Reports

Verona Pharma begins Phase 2 clinical trial evaluating nebulised RPL554 as add-on therapy